Special Issue

Design and Synthesis of Novel Antibiotics

Message from the Guest Editors

The increasing resistance of microorganisms to the currently available antimicrobials is a serious problem globally, resulting in significant morbidity, mortality and healthcare costs. The problem of antimicrobial resistance is especially urgent in terms of antibiotic resistance bacteria, and especially alarming is the rapid global spread of multi- and pan-resistant bacteria. Thus, there is an urgent need to search for new, alternative classes of effective antibiotics with novel modes of action and low toxicity. This Special Issue, "Design and Synthesis of Novel Antibiotics", aims to present the latest scientific research in the field of the design, synthesis, characterization and development of new antibiotics. The manuscript should include the structural characterization of new compounds and the evaluation of their biological activity and cytotoxicity. Reviews and research articles will be considered for publication.

Guest Editors

Dr. Katarzyna Turecka

Department of Pharmaceutical Microbiology, Medical University of Gdańsk, Gen. J. Hallera Av. 107, 80-416 Gdańsk, Poland

Dr. Kenneth Ikenna Onyedibe

Department of Chemistry, Purdue University, 560 Oval Drive, West Lafayette, IN 47907, USA

Deadline for manuscript submissions

closed (31 August 2024)

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/146134

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI